Importantly, TP53 inactivation in MDS is not limited to point mutations but may also involve additional mechanisms of loss of genetic material, including copy-neutral loss of heterozygosity and segmental deletions, which further contribute to loss of tumor suppressor function [74,75]. Here, TP53 is linked to myelodysplastic syndrome.